Background: Sarepta Therapeutics reported today additional long-term clinical efficacy and safety data from its pivotal phase 2b program of eteplirsen to treat Duchenne muscular dystrophy (DMD). The data demonstrated that over a three-year period of time, trial participants who were treated with eteplirsen experienced a slower rate of decline and were, on average, able to . . .
In September, the Data Safety and Monitoring Board (DSMB), constituted to oversee the Diaphragm Pacing System in Participants with Amyotrophic Lateral Sclerosis (DPS in ALS) study, being conducted in the United States, issued a recommendation that new enrollment be halted. At the same time, the DSMB recommended that patients already randomized to the diaphragm pacing . . .
– Importance of USPTO decision not ascertainable until determinations are rendered in two remaining composition interferences and planned appeal – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 30, 2015– Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has . . .
Criss Hartzell, professor of cell biology at Emory University School of Medicine in Atlanta, Ga., recently was awarded an MDA research grant to study the ANO5 gene. Mutations in the gene have been implicated in both type 2L limb-girdle muscular dystrophy (LGMD) and a subtype of Miyoshi distal muscular dystrophy (a type of distal muscular dystrophy, . . .
Priority of U.S. Patent Claims Confirmed by U.S. Patent Trial and Appeal Board (PTAB) SAN RAFAEL, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) — BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Patent Trial and Appeal Board (PTAB) issued a decision in favor of BioMarin’s claims to the use of exon 51 antisense oligonucleotides to treat . . .
September 9, 2015 Background: On the afternoon of Wednesday, Sept. 9, a hit-and-run driver tragically struck Lansing, Mich. Local 421 fire fighter Dennis Rodeman during an MDA Fill the Boot drive. He later died at a local hospital as a result of the injuries he suffered. Police have apprehended the man driving the vehicle and . . .
Alliance is part of an MDA initiative to establish new collaborative partnerships CHICAGO, September 2, 2015 – The Muscular Dystrophy Association (MDA) and the Friedreich’s Ataxia Research Alliance (FARA) today announced a partnership that will pave the way for advancements in Friedreich’s Ataxia (FA) research, therapeutic development and clinical care, thus deepening understanding of the . . .
By Laura Hagerty, Ph.D., MDA’s DMD Scientific Program Officer On September 7, 2015, MDA will rally alongside our Duchenne muscular dystrophy (DMD) community — kids, adults, families, caregivers and others — as we recognize World Duchenne Awareness Day. And as we move toward that day, there’s a palpable feeling of excitement in the air. For . . .
By Amanda M. Haidet-Phillips, Ph.D., MDA’s ALS Scientific Program Officer As the month of August comes to an end, and the 2015 ALS Ice Bucket Challenge with it, I want to share with you some exciting new research news. MDA has announced the award of 36 new research and development grants, totaling nearly $10 million, . . .
CHICAGO, August, 27, 2015 — Prominent business and community leaders from across the country have been appointed to the Muscular Dystrophy Association’s Board of Directors. As members of the board, these 20 men and women will volunteer assistance and counsel to support MDA’s mission to fund lifesaving research, provide comprehensive care through its services and . . .
